MAP2K1 (mitogen-activated protein kinase kinase 1) is a dual-specificity protein kinase that serves as a critical node in the MAPK/ERK signaling cascade. Upon activation by upstream RAF proteins following growth factor stimulation, MAP2K1 phosphorylates both threonine and tyrosine residues on ERK1/ERK2, propagating signals that regulate cell growth, differentiation, survival, and adhesion 1. MAP2K1 mutations drive multiple human malignancies and inflammatory diseases. Activating MAP2K1 mutations occur in approximately 20% of Erdheim-Chester disease cases and are found across histiocytic neoplasms, demonstrating remarkable sensitivity to MEK inhibitors with 89% response rates regardless of additional mutations 21. In melanoma, MAP2K1 mutations (found in ~8% of cases) are associated with distinct histopathologic features including spitzoid cytomorphology and in-frame deletions, and predict superior responses to anti-CTLA-4 immunotherapy but not anti-PD-1 monotherapy 34. The functional consequences of MAP2K1 variants vary significantly by mutation type and RAF-dependency, with differential sensitivities to BRAF and MEK inhibitor combinations, necessitating individualized therapeutic assessment 5. MEK1/2 inhibitors like selumetinib provide clinical benefit in neurofibromatosis type 1-associated tumors 6, establishing MAP2K1 inhibition as a broadly effective therapeutic strategy across diverse MAPK-driven diseases.